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A. SETTING THE STAGE
The scientific challenges facing HIV-1 vaccine development are 
unprecedented in the history of vaccinology. As a result, investigators, 
funders, and other stakeholders generally agree that “game-changing” 
ideas are required. While innovation can certainly arise from investiga-
tors at all career stages, young and early-career investigators, defined 
as those under 40 years of age or within 10 years of their final degree 
or clinical training, are especially key contributors of novel and trans-
formative ideas. Young and early-career investigators bring energy, 
enthusiasm, and fresh perspectives that are unbiased by prevailing 
dogma and that are essential to scientific progress.
Demographic analysis supports the premise that transformative new 
ideas often originate with young and early-career investigators1. Nobel 
laureates Harold Varmus, David Baltimore, James Watson and Dorothy 
Hodgkin all made their groundbreaking discoveries before the age of 
30. Charles Darwin conceived the theory of natural selection when he 
was 29. Albert Einstein published his papers about special relativity and 
quantum mechanics when he was 26. Isaac Newton began developing 
calculus and the law of gravitation at 25. This anecdotal evidence, as 
well as demographic analysis of Nobel laureates1, suggests that young 
and early-career investigators are a major source of innovative ideas 
that often drive key paradigm shifts in all areas of science.
B. CHALLENGES AND OPPORTUNITIES
The Global HIV Vaccine Enterprise established a committee of Young 
and Early Career Investigators (YECIs) in 2008 to define key bottle-
necks currently faced by YECIs in the HIV-1 vaccine field and to sug-
gest potential solutions. Members of this committee were recruited 
from both the developed and the developing world and represent a 
wide diversity of backgrounds and scientific interests.
The YECI committee (http://www.vaccineenterprise.org/content/
young-and-early-career-investigators-yeci), organized a series of 
meetings and consultations in 2008 and 2009 to solicit broad per-
spectives from young investigators, senior investigators, funders, 
and other stakeholders to inform the development of this report. 
Open sessions were held at the 2008 International AIDS conference 
in Mexico City, the AIDS Vaccine 2008 conference in Cape Town, the 
2009 Keystone Symposium on HIV Vaccines, and the AIDS Vaccine 
2009 conference in Paris. Additional information was obtained 
through surveys, open discussions, small group meetings, and online 
communications.
The major obstacles facing YECIs in the HIV-1 vaccine field that 
were identified can be summarized as follows:
(i) The perception of HIV-1 vaccine research as saturated, competi-
tive, empiric, and unproductive may inhibit the recruitment of the best 
and the brightest YECIs to the field.
(ii) The increasingly large-scale, complex, and interdisciplinary 
nature of HIV-1 vaccine research requires multidisciplinary training 
with broad knowledge in multiple areas. This will require redefining 
traditional mentorship, training, and career development pathways.
(iii) The lack of access to key datasets and resources may impede 
YECI research and creativity.
(iv) YECIs currently face unprecedented challenges in securing ini-
tial funding to launch what should be one of the most creative phases 
of their careers. These funding challenges are further exacerbated by 
the lack of sufficient numbers of faculty positions and protected career 
development pathways at academic institutions2. From 1980 to 2007, 
the average age of principal investigators funded by the US National 
Institutes of Health (NIH) has increased markedly (Fig. 1a), and the 
age of first-time NIH grant recipients has risen to an all-time high 
of 41 years of age (Fig. 1b). These data suggest that the turnover of 
resources, laboratory space, and academic positions to young inves-
tigators is inadequate.
(v) Moreover, visibility and leadership representation of YECIs in 
the HIV-1 vaccine field represent further challenges for their develop-
ment as independent investigators.
(vi) Finally, YECIs who live and work in the developing world, 
where most of the new HIV-1 infections occur, represent a critical 
and underutilized reservoir of skill, innovation, and determination. 
YECIs in the developing world face profound logistic, funding, men-
torship, institutional, and career development challenges that require 
particular attention.
In this report, we offer potential solutions to these problems. Our 
primary goal is not to advocate for increased support for YECIs per se, 
but rather to ensure that YECIs are able to contribute maximumally to 
the development of an HIV-1 vaccine. The success of the HIV vaccine 
effort will undoubtedly depend on the innovation, enthusiasm, and 
engagement of the next generation of investigators.
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increasing the number of start-up funds and faculty positions for YECIs 
would greatly facilitate the difficult transition from postdoctoral fellow 
to independent investigator. Fourth, a centralized, online resource could 
be created and hosted by the Enterprise to support a global commu-
nity of YECIs by providing up-to-date information about funding and 
employment opportunities, mentors, training courses, workshops, and 
other activities. This resource could also serve as a forum for discussion 
and a virtual meeting place for YECIs.
To address the particular needs of YECIs in the developing world, we 
recommend the creation of additional regional Centers of Excellence 
at institutions that have the necessary infrastructure and critical mass. 
Existing Centers of Excellence in developing countries should also be 
strengthened. Long-term funding to such Centers could be linked to 
ongoing recruitment and development of YECIs. These Centers would be 
expected to provide mentorship, training, research and networking infra-
structure, exposure, and solid career development paths and would also 
include faculty partnerships and YECI exchange programs with research 
institutions in the developed world. Coordinated establishment, funding, 
and local ownership and leadership of these Centers would be crucial to 
ensure sustainability.
Data Sharing and Open Access
We also recommend increased open access to data and reagents in the 
HIV-1 vaccine field to ensure that YECIs (as well as others) can contribute 
C. RECOMMENDATIONS
To address these challenges, we recommend the development of 
a multi-component YECI Initiative as part of the 2010 Scientific 
Strategic Plan of the Global HIV Vaccine Enterprise3. This YECI 
Initiative involves a coordinated strategy (Table 1) to establish a new 
infrastructure and culture that will best enable YECIs to develop and 
to explore new ideas in the HIV-1 vaccine field. The current paucity 
of independently funded YECIs may represent one of the most critical 
impediments to innovation in the HIV-1 vaccine field.
Mentorship
We first suggest that outstanding mentorship in the HIV-1 vaccine 
field should be recognized and encouraged by establishing Excellence 
in Mentoring Awards. These awards would be chosen by YECIs and 
would include mentors from both the developed and developing worlds. 
Hosted by the Enterprise, these awards could be presented during the 
plenary sessions of the annual AIDS Vaccine Conferences. Academic 
institutions should also be encouraged to increase their emphasis on 
mentorship as a criterion for promotion. Our goal is to ensure that these 
Mentorship Awards are highly prestigious awards that recognize the full 
responsibility of senior colleagues not only to conduct their own research 
but also to ensure the success of the next generation of investigators.
Career Development
Training and career development pathways urgently need to be reexam-
ined in the face of the profoundly changing way in which biomedical 
research is conducted today. To that end, we recommend a number of 
discrete action items: first, increased numbers of transportable post-
doctoral salary support fellowships would allow trainees the flexibility 
to define and to explore their own ideas. Second, more comprehensive 
multidisciplinary training opportunities could be provided, such as 
expanding the popular satellite workshops that are focused on a variety 
of scientific and career development topics and that are held in conjunc-
tion with major scientific conferences. The goal of these training ses-
sions would be to provide more comprehensive educational experiences 
without increasing the overall length of postdoctoral training. Third, 
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Table 1.  Summary of priorities and recommendations of the 
YECI Initiative.
Mentorship, Career Development, and Open Access
1. Establish Excellence in Mentoring Awards
2. Strengthen training and career development pathways
   a. Increase numbers of transportable postdoctoral salary support fellowships
   b. Offer more comprehensive multidisciplinary training opportunities
   c. Increase availability of start-up funds and faculty positions
   d. Create a centralized global electronic YECI community
3. Create and enhance regional Centers of Excellence in the developing world
4. Increase open access to data and resources
Novel Funding Approaches
1. Establish funds to recruit YECIs from traditionally non-HIV-1 fields
2. Develop targeted initial independent grant programs for YECIs both in the 
developed and in the developing world
3. Award research grants from YECIs and established investigators at similar 
success rates
4. Set quantitative targets for funding of YECI PIs in the context of large 
consortia
Visibility and Leadership Representation
1. Encourage a cultural shift in which YECIs would have increased visibility 
and greater leadership representation
2. Set quantitative targets for conference organizers to include YECIs as 
invited speakers at international conferences
3. Include YECIs on peer review panels for grant proposals, editorial boards 
for journals, and scientific leadership groups of major consortia and other 
decision-making bodies
Figure 1  Distribution of NIH research project grants by age between 1980 
and 2007 (http://grants.nih.gov). (a) Aging population of all investigators 
receiving NIH research project grants resulting in the median age increasing 
from 38 years in 1980 to 49 years in 2007. (b) Increasing age of first-time 
recipients of NIH research project grants. The median age of a first-time 
investigator has increased from 34 years in 1980 to 41 years in 2007. 
(First-time investigators are defined as principal investigators who have not 
previously competed successfully for a major NIH research grant award.)
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sciences. In particular, YECIs represent a critically important source 
of innovation for the field4,5. The present report provides a frame-
work of the key challenges faced by YECIs in the HIV-1 vaccine field 
and offers potential approaches to solving these problems.
A number of meaningful steps have already been taken to address 
these problems since the Enterprise first championed the strategic 
importance of YECIs for the HIV-1 vaccine field. For example, by 
increasing the research project grant payline for new investigators, 
the National Institute of Allergy and Infectious Diseases (NIAID) 
achieved comparable levels of funding for new and established inves-
tigators in 2009. In addition, the NIH Director’s Office has established 
an Early Independence Investigators program that, while not specifi-
cally targeted to HIV, may serve as an excellent model for HIV YECIs 
(http://nihroadmap.nih.gov/independentfellows/). The Wellcome Trust 
has recently articulated a new policy that focuses on people rather 
than projects with a particular emphasis on young investigators. 
The Center for HIV/AIDS Vaccine Immunology (CHAVI) and the 
Collaboration for AIDS Vaccine Discovery (CAVD) have established 
programs that regularly recognize young investigators, and NIAID has 
committed new funding that has been awarded by the HIV Vaccine 
Trials Network (HVTN), and CHAVI to early-stage investigators 
with projects that aim to bridge the gaps between nonhuman pri-
mate and clinical research. In addition, conference organizers appear 
to be placing a higher priority on inviting YECI speakers at regional 
and international conferences. These and other programs suggest the 
beginning of an important cultural shift aimed at encouraging YECIs 
and ensuring that their creativity and innovation will help to drive the 
HIV-1 vaccine field forward. We strongly applaud this trend, although 
current efforts are still inadequate, particularly in the developing 
world. We believe that the recommendations proposed in this report 
will address many of the challenges currently faced by YECIs and by 
so doing will accelerate the development of an HIV-1 vaccine.
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maximumally to the collaborative HIV vaccine efforts. Arguably data 
obtained in whole or in part with public or philanthropic funds should 
be made openly accessible as soon as practically possible. To facilitate this 
goal, a centralized HIV-1 database resource could be created to collate 
and to provide open access to datasets and to platforms that facilitate 
rapid sharing of methodologies and reagents. In addition, we endorse 
open access publication and the creation of a pre-print server of peer-
reviewed HIV-1 vaccine research.
Novel Funding Approaches
We next suggest a series of approaches to facilitate improved independent 
funding opportunities for YECIs. First, a fund could be established to 
provide research support to YECIs from traditionally non-HIV fields who 
are interested in becoming engaged in HIV-1 vaccine research. The goal 
would be to recruit and to retain the best young minds and to increase 
the breadth of expertise in the HIV-1 vaccine field. Second, targeted ini-
tial independent grant programs could be developed for YECIs both in 
the developed and in the developing world to facilitate transitions from 
postdoctoral to independent investigator. Third, funders should strive to 
award research grants to YECIs and established investigators at similar 
success rates to compensate for potential biases in the peer review pro-
cess. Fourth, quantitative targets should be set for funding of YECI PIs 
in the context of programs and large consortia. We would suggest, for 
example, that at least 20% of research funds in large consortia should be 
targeted to YECI PIs if proposed concepts are scientifically meritorious. 
This strategy would increase funding opportunities for YECIs as well as 
help solidify their leadership roles in the context of consortia.
Visibility and Leadership Representation
Finally, we advocate for a cultural shift in which YECIs would have 
increased visibility and an enhanced leadership role in the HIV-1 vac-
cine field. For example, we encourage quantitative targets for conference 
organizers to include YECIs as invited speakers. We recommend that at 
least 25% of plenary lectures and 50% of all oral presentations at interna-
tional conferences be given by YECIs. We also suggest that peer review 
panels for grant proposals, editorial boards for journals, and scientific 
leadership groups of major consortia and other decision-making bodies 
should include YECIs. Particular emphasis should be placed on including 
YECIs from the developing world.
D. CONCLUSIONS
The multifaceted YECI Initiative proposed in this report is aligned 
with the overall goals of the 2010 Scientific Strategic Plan of the 
Global HIV Vaccine Enterprise and especially the need to attract and 
to develop YECIs to harness the ongoing revolution in the biomedical 
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